Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide/Irinotecan +/- Bevacizumab in Recurrent Medulloblastoma/PNET
NCT01217437Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in medulloblastoma and primitive neuroectodermal tumor (PNET), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Nov 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NCT01217437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217437.